Flavonoids in non-alcoholic fatty liver disease: classification, therapeutic potential, and underlying mechanisms

doi:10.5246/jcps.2025.09.059

Abstract

Abstract:

Non-alcoholic fatty liver disease (NAFLD) has emerged as a predominant contributor to chronic liver disorders and hepatocellular carcinoma, representing a significant global health burden. Mounting evidence has implicated obesity, metabolic syndrome, oxidative stress, and insulin resistance (IR) as central drivers of NAFLD pathogenesis. Despite the absence of approved pharmacological therapies or clearly defined molecular targets, flavonoids have garnered increasing attention for their therapeutic potential. As key bioactive molecules, flavonoids may modulate critical gene networks implicated in the progression of NAFLD. In addition to mitigating lipid accumulation induced by IR, these compounds exert multifaceted regulatory effects by modulating proteasome activity, intracellular signaling cascades, gene transcription, and inflammatory processes that contribute to hepatic lipid dysregulation.

Key words: Non-alcoholic fatty liver disease (NAFLD), Flavonoids, Natural products, Pharmacology

Supporting:

Xinyu Wang, Shicheng Li, Mingjing Luo, Dan Li, Chuyu Wang, Xiaoli He, Guang Hu. Flavonoids in non-alcoholic fatty liver disease: classification, therapeutic potential, and underlying mechanisms[J]. Journal of Chinese Pharmaceutical Sciences, 2025, 34(9): 801-820.

Figures/Tables 2

References 97

[1]	Paik, J.M.; Henry, L.; Younossi, Y.; Ong, J.; Alqahtani, S.; Younossi, Z.M. The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019. Hepatol. Commun. 2023, 7, e0251.
[2]	Cobbina, E.; Akhlaghi, F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab. Rev. 2017, 49, 197–211.
[3]	Huang, G.; Wallace, D.F.; Powell, E.E.; Rahman, T.; Clark, P.J.; Subramaniam, V.N. Gene variants implicated in steatotic liver disease: opportunities for diagnostics and therapeutics. Biomedicines. 2023, 11, 2809.
[4]	Chen, S.; Wang, X.J.; Cheng, Y.; Gao, H.S.; Chen, X.H. A review of classification, biosynthesis, biological activities and potential applications of flavonoids. Molecules. 2023, 28, 4982.
[5]	Shin, J.H.; Jung, J.H. Non-alcoholic fatty liver disease and flavonoids: Current perspectives. Clin. Res. Hepatol. Gastroenterol. 2017, 41, 17–24.
[6]	Roy, J.R.; Janaki, C.S.; Jayaraman, S.; Veeraraghavan, V.P.; Periyasamy, V.; Balaji, T.; Vijayamalathi, M.; Bhuvaneswari, P.; Swetha, P. Hypoglycemic potential of Carica papaya in liver is mediated through IRS-2/PI3K/SREBP-1c/GLUT2 signaling in high-fat-diet-induced type-2 diabetic male rats. Toxics. 2023, 11, 240.
[7]	Li, Q.; Tan, J.X.; He, Y.; Bai, F.; Li, S.W.; Hou, Y.W.; Ji, L.S.; Gao, Y.T.; Zhang, X.; Zhou, Z.H.; Yu, Z.; Fang, M.; Gao, Y.Q.; Li, M. Atractylenolide III ameliorates non-alcoholic fatty liver disease by activating hepatic adiponectin receptor 1-mediated AMPK pathway. Int. J. Biol. Sci. 2022, 18, 1594–1611.
[8]	Afrisham, R.; Alasvand, G.; Jadidi, Y.; Farrokhi, V.; Moradi, N.; Alizadeh, S.; Fadaei, R. CCN3/NOV serum levels in non-alcoholic fatty liver disease (NAFLD) patients in comparison with the healthy group and their correlation with TNF-α and IL-6. Curr. Mol. Med. 2025, 25, 605-613.
[9]	Gonzalez, A.; Huerta-Salgado, C.; Orozco-Aguilar, J.; Aguirre, F.; Tacchi, F.; Simon, F.; Cabello-Verrugio, C. Role of oxidative stress in hepatic and extrahepatic dysfunctions during nonalcoholic fatty liver disease (NAFLD). Oxid. Med. Cell Longev. 2020, 2020, 1617805.
[10]	Yu, Y.M.; Wu, D.X.; Li, Y.W.; Qiao, H.; Shan, Z.F. Ketamine enhances autophagy and endoplasmic reticulum stress in rats and SV-HUC-1 cells via activating IRE1-TRAF2-ASK1-JNK pathway. Cell Cycle. 2021, 20, 1907–1922.
[11]	Song, Z.M.; Liu, F.; Chen, Y.M.; Liu, Y.J.; Wang, X.D.; Du, S.Y. CTGF-mediated ERK signaling pathway influences the inflammatory factors and intestinal flora in ulcerative colitis. Biomed. Pharmacother. 2019, 111, 1429–1437.
[12]	Marmolejo-Garza, A.; Krabbendam, I.E.; Luu, M.D.A.; Brouwer, F.; Trombetta-Lima, M.; Unal, O.; O’Connor, S.J.; Majerníková, N.; Elzinga, C.R.S.; Mammucari, C.; Schmidt, M.; Madesh, M.; Boddeke, E.; Dolga, A.M. Negative modulation of mitochondrial calcium uniporter complex protects neurons against ferroptosis. Cell Death Dis. 2023, 14, 772.
[13]	Papsdorf, K.; Miklas, J.W.; Hosseini, A.; Cabruja, M.; Morrow, C.S.; Savini, M.; Yu, Y.; Silva-García, C.G.; Haseley, N.R.; Murphy, L.M.; Yao, P.; de Launoit, E.; Dixon, S.J.; Snyder, M.P.; Wang, M.C.; Mair, W.B.; Brunet, A. Lipid droplets and peroxisomes are co-regulated to drive lifespan extension in response to mono-unsaturated fatty acids. Nat. Cell Biol. 2023, 25, 672–684.
[14]	Chen, Z.; Tian, R.F.; She, Z.G.; Cai, J.J.; Li, H.L. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic. Biol. Med. 2020, 152, 116–141.
[15]	Li, X.; Cheng, Y.H.; Zhong, X.L.; Zhang, B.; Bao, Z.W.; Zhang, Y.; Wang, Z.G. Nuclear factor erythroid 2-related factor 2 activation mediates hyperhomocysteinemia-associated lipolysis suppression in adipocytes. Exp. Biol. Med. 2018, 243, 926–933.
[16]	Adinolfi, S.; Patinen, T.; Jawahar Deen, A.; Pitkänen, S.; Härkönen, J.; Kansanen, E.; Küblbeck, J.; Levonen, A.L. The KEAP1-NRF2 pathway: targets for therapy and role in cancer. Redox Biol. 2023, 63, 102726.
[17]	Suzuki, T.; Yamamoto, M. Stress-sensing mechanisms and the physiological roles of the Keap1–Nrf2 system during cellular stress. J. Biol. Chem. 2017, 292, 16817–16824.
[18]	Gu, Z.M.; Meng, J.Y.; Zhong, W.Q.; Lan, C.J.; Tan, Q.Q.; Xiang, X.L.; Zhou, H.; Liao, X. The role of the KEAP1-NRF2 signaling pathway in form deprivation myopia guinea pigs. BMC Ophthalmol. 2024, 24, 497.
[19]	Orrù, C.; Perra, A.; Kowalik, M.A.; Rizzolio, S.; Puliga, E.; Cabras, L.; Giordano, S.; Columbano, A. Distinct mechanisms are responsible for Nrf2-Keap1 pathway activation at different stages of rat hepatocarcinogenesis. Cancers. 2020, 12, 2305.
[20]	Kasai, S.Y.; Kokubu, D.; Mizukami, H.; Itoh, K. Mitochondrial reactive oxygen species, insulin resistance, and Nrf2-mediated oxidative stress response-toward an actionable strategy for anti-aging. Biomolecules. 2023, 13, 1544.
[21]	Akl, M.G.; Li, L.; Baccetto, R.; Phanse, S.; Zhang, Q.Z.; Trites, M.J.; McDonald, S.; Aoki, H.; Babu, M.H.; Widenmaier, S.B. Complementary gene regulation by NRF1 and NRF2 protects against hepatic cholesterol overload. Cell Rep. 2023, 42, 112399.
[22]	Wang, Y.C.; Liu, X.X.; Shi, H.; Yu, Y.; Yu, Y.; Li, M.H.; Chen, R.Z. NLRP3 inflammasome, an immune-inflammatory target in pathogenesis and treatment of cardiovascular diseases. Clin. Transl. Med. 2020, 10, 91–106.
[23]	Guo, T.W.; Pan, Y.; Yang, L.; Chen, G.; Deng, J.; Zhu, L.C. Flavonoid compound from Agrimonia Pilosa Ledeb improves adipose insulin resistance by alleviating oxidative stress and inflammation. BMC Complement. Med. Ther. 2023, 23, 322.
[24]	Wang, Y.; Chen, C.J.; Chen, J.J.; Sang, T.T.; Peng, H.; Lin, X.J.; Zhao, Q.; Chen, S.J.; Eling, T.; Wang, X.Y. Overexpression of NAG-1/GDF15 prevents hepatic steatosis through inhibiting oxidative stress-mediated dsDNA release and AIM2 inflammasome activation. Redox Biol. 2022, 52, 102322.
[25]	Xia, D.Y.; Yuan, J.L.; Jiang, X.C.; Qi, M.; Lai, N.S.; Wu, L.Y.; Zhang, X.S. SIRT1 promotes M2 microglia polarization via reducing ROS-mediated NLRP3 inflammasome signaling after subarachnoid hemorrhage. Front. Immunol. 2021, 12, 770744.
[26]	Saeed, A.; Dullaart, R.P.F.; Schreuder, T.C.M.A.; Blokzijl, H.; Faber, K.N. Disturbed vitamin a metabolism in non-alcoholic fatty liver disease (NAFLD). Nutrients. 2017, 10, 29.
[27]	Liu, M.L.; Park, S. The role of PNPLA3 _rs738409 gene variant, lifestyle factors, and bioactive compounds in nonalcoholic fatty liver disease: a population-based and molecular approach towards healthy nutrition. Nutrients. 2024, 16, 1239.
[28]	Sherman, D.J.; Liu, L.; Mamrosh, J.L.; Xie, J.S.; Ferbas, J.; Lomenick, B.; Ladinsky, M.S.; Verma, R.; Rulifson, I.C.; Deshaies, R.J. The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics. bioRxiv: the preprint server for biology. 2023, 2023.10.13.562302.
[29]	Rojas, Á.; Gallego, P.; Gil-Gómez, A.; Muñoz-Hernández, R.; Rojas, L.; Maldonado, R.; Gallego-Durán, R.; García-Valdecasas, M.; Del Campo, J.A.; Bautista, J.D.; Romero-Gómez, M. Natural extracts abolished lipid accumulation in cells harbouring non-favourable PNPLA3 genotype. Ann. Hepatol. 2018, 17, 242–249.
[30]	Li, F.J.; Liu, G.L.; Xue, P.L.; Ren, Z.; Dai, P.F.; Niu, W.Y.; Xin, M. YiQi YangYin decoction attenuates nonalcoholic fatty liver disease in type 2 diabetes rats. Evid. Based Complement. Alternat. Med. 2021, 2021, 5511019.
[31]	Chagas, M.D.S.S.; Behrens, M.D.; Moragas-Tellis, C.J.; Penedo, G.X.M.; Silva, A.R.; Gonçalves-de-Albuquerque, C.F. Flavonols and flavones as potential anti-inflammatory, antioxidant, and antibacterial compounds. Oxid. Med. Cell Longev. 2022, 2022, 9966750.
[32]	Xie, R.J.; Zhao, W.J.; Lowe, S.; Bentley, R.; Hu, G.Q.; Mei, H.Y.; Jiang, X.F.; Sun, C.Y.; Wu, Y.; Liu, Y.Y. Quercetin alleviates kainic acid-induced seizure by inhibiting the Nrf2-mediated ferroptosis pathway. Free Radic. Biol. Med. 2022, 191, 212–226.
[33]	Hsu, M.C.; Guo, B.C.; Chen, C.H.; Hu, P.A.; Lee, T.S. Apigenin ameliorates hepatic lipid accumulation by activating the autophagy-mitochondria pathway. J. Food Drug Anal. 2021, 29, 240–254.
[34]	Tang, Q.Q.; Wang, Z.D.; An, X.H.; Zhou, X.Y.; Zhang, R.Z.; Zhan, X.; Zhang, W.; Zhou, J. Apigenin ameliorates H₂O₂-induced oxidative damage in melanocytes through nuclear factor-E2-related factor 2 (Nrf2) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathways and reducing the generation of reactive oxygen species (ROS) in zebrafish. Pharmaceuticals. 2024, 17, 1302.
[35]	Ares, A.M.; Bernal, J.; Janvier, A.; Toribio, L. Chiral and achiral separation of ten flavanones using supercritical fluid chromatography. Application to bee pollen analysis. J. Chromatogr. A. 2022, 1685, 463633.
[36]	Silva, B.P.; Souza, R.S.; Yamaguchi, K.L.; Silva, F.A.; Koolen, H.F.; Veiga Junior, V.F.; Lima, E.S. Hepatoprotective and antioxidant activities of phenolic-rich extract from shell of nut Brazil (Bertholletia excelsa H.B.K.). Braz J. Biol. 2024, 84, e288958.
[37]	Abderrazak, A.; Syrovets, T.; Couchie, D.; El Hadri, K.; Friguet, B.; Simmet, T.; Rouis, M. NLRP3 inflammasome: From a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases. Redox Biol. 2015, 4, 296–307.
[38]	Sharifi-Rad, J.; Quispe, C.; Imran, M.; Rauf, A.; Nadeem, M.; Gondal, T.A.; Ahmad, B.; Atif, M.; Mubarak, M.S.; Sytar, O.; Zhilina, O.M.; Garsiya, E.R.; Smeriglio, A.; Trombetta, D.; Pons, D.G.; Martorell, M.; Cardoso, S.M.; Razis, A.F.A.; Sunusi, U.; Kamal, R.M.; Rotariu, L.S.; Butnariu, M.; Docea, A.O.; Calina, D. Genistein: an integrative overview of its mode of action, pharmacological properties, and health benefits. Oxid. Med. Cell Longev. 2021, 2021, 3268136.
[39]	Al-Khayri, J.M.; Sahana, G.R.; Nagella, P.; Joseph, B.V.; Alessa, F.M.; Al-Mssallem, M.Q. Flavonoids as potential anti-inflammatory molecules: a review. Molecules. 2022, 27, 2901.
[40]	Suzuki, T.; Ohishi, T.; Tanabe, H.; Miyoshi, N.; Nakamura, Y. Anti-inflammatory effects of dietary polyphenols through inhibitory activity against metalloproteinases. Molecules. 2023, 28, 5426.
[41]	Li, R.L.; Wang, L.Y.; Liu, S.Q.; Duan, H.X.; Zhang, Q.; Zhang, T.; Peng, W.; Huang, Y.L.; Wu, C.J. Natural flavonoids derived from fruits are potential agents against atherosclerosis. Front. Nutr. 2022, 9, 862277.
[42]	Watanabe, N.; Inoue, K.; Hara, H.; Midorikawa, M.; Ohta, M.; Ohkura, N. Randomised, double-blind, parallel group comparison of Ashitaba (Angelica Keiskei) chalcone effects on visceral fat areas and waist circumference of overweight persons. Int. J. Food Sci. Nutr. 2024, 75, 426–435.
[43]	Olaokun, O.O.; Zubair, M.S. Antidiabetic activity, molecular docking, and ADMET properties of compounds isolated from bioactive ethyl acetate fraction of Ficus lutea leaf extract. Molecules. 2023, 28, 7717.
[44]	Liu, C.Q.; Pan, X.Y.; Hao, Z.H.; Wang, X.; Wang, C.; Song, G.Y. Resveratrol suppresses hepatic fatty acid synthesis and increases fatty acid β-oxidation via the microRNA-33/SIRT6 signaling pathway. Exp. Ther. Med. 2024, 28, 326.
[45]	Fotschki, B.; Juśkiewicz, J.; Jurgoński, A.; Sójka, M. Fructo-oligosaccharides and pectins enhance beneficial effects of raspberry polyphenols in rats with nonalcoholic fatty liver. Nutrients. 2021, 13, 833.
[46]	Ku, Y.S.; Ng, M.S.; Cheng, S.S.; Lo, A.W.; Xiao, Z.X.; Shin, T.S.; Chung, G.; Lam, H.M. Understanding the composition, biosynthesis, accumulation and transport of flavonoids in crops for the promotion of crops as healthy sources of flavonoids for human consumption. Nutrients. 2020, 12, 1717.
[47]	Wei, H.W.; Zhao, T.; Liu, X.L.; Ding, Q.T.; Yang, J.R.; Bi, X.Y.; Cheng, Z.Q.; Ding, C.B.; Liu, W.C. Mechanism of action of dihydroquercetin in the prevention and therapy of experimental liver injury. Molecules. 2024, 29, 3537.
[48]	Oteiza, P.I.; Cremonini, E.; Fraga, C.G. Anthocyanin actions at the gastrointestinal tract: relevance to their health benefits. Mol. Aspects Med. 2023, 89, 101156.
[49]	Khan, N.N.; Zurayyir, E.J.; Almuslem, M.Y.; Alshamrani, R.; Alamri, R.A.; Sulaimani, G.H.T.; Sulimani, M.H.T.; Albalawi, M.S.F.; Alzehair Alqahani, R.M.; Alanazi, E.M.; Aljawi, H.H.; Alsuliman, J.A. Anthocyanins as adjuvant treatment for non-alcoholic fatty liver disease: a systematic review and meta-analysis. Cureus. 2024, 16, e63445.
[50]	Liu, Q.S.; Pan, R.; Ding, L.; Zhang, F.L.; Hu, L.F.; Ding, B.; Zhu, L.; Xia, Y.L.; Dou, X.B. Rutin exhibits hepatoprotective effects in a mouse model of non-alcoholic fatty liver disease by reducing hepatic lipid levels and mitigating lipid-induced oxidative injuries. Int. Immunopharmacol. 2017, 49, 132–141.
[51]	Noor-E-Tabassum, Das, R.; Lami, M.S.; Chakraborty, A.J.; Mitra, S.; Tallei, T.E.; Idroes, R.; Mohamed, A.A.; Hossain, M.J.; Dhama, K.; Mostafa-Hedeab, G.; Emran, T.B. Ginkgo biloba: a treasure of functional phytochemicals with multimedicinal applications. Evid. Based Complement Altern. Med. 2022, 2022, 8288818.
[52]	Yang, K.L.; Chen, J.P.; Zhang, T.Q.; Yuan, X.; Ge, A.Q.; Wang, S.S.; Xu, H.; Zeng, L.T.; Ge, J.W. Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis. Front. Immunol. 2022, 13, 949746.
[53]	Sahin, E.; Bagci, R.; Bektur Aykanat, N.E.; Kacar, S.; Sahinturk, V. Silymarin attenuated nonalcoholic fatty liver disease through the regulation of endoplasmic reticulum stress proteins GRP78 and XBP-1 in mice. J. Food Biochem. 2020, 44, e13194.
[54]	Lu, Z.; Liu, L.; Zhao, S.X.; Zhao, J.T.; Li, S.J.; Li, M.Y. Apigenin attenuates atherosclerosis and non-alcoholic fatty liver disease through inhibition of NLRP3 inflammasome in mice. Sci. Rep. 2023, 13, 7996.
[55]	Yue, S.W.; Xue, N.; Li, H.L.; Huang, B.S.; Chen, Z.; Wang, X. Hepatoprotective effect of apigenin against liver injury via the non-canonical NF-κB pathway in vivo and in vitro. Inflammation. 2020, 43, 1634–1648.
[56]	Lv, Y.N.; Gao, X.N.; Luo, Y.; Fan, W.T.; Shen, T.T.; Ding, C.C.; Yao, M.; Song, S.Q.; Yan, L.P. Apigenin ameliorates HFD-induced NAFLD through regulation of the XO/NLRP3 pathways. J. Nutr. Biochem. 2019, 71, 110–121.
[57]	Sangeetha, R. Luteolin in the management of type 2 diabetes mellitus. Curr. Res. Nutr. Food Sci. J. 2019, 7, 393–398.
[58]	Zhu, K.; Zeng, H.Z.; Yue, L.; Huang, J.N.; Ouyang, J.; Liu, Z.H. The protective effects of L-theanine against epigallocatechin gallate-induced acute liver injury in mice. Foods. 2024, 13, 1121.
[59]	Ahmed, E.S.; Mohamed, H.E.; Farrag, M.A. Luteolin loaded on zinc oxide nanoparticles ameliorates non-alcoholic fatty liver disease associated with insulin resistance in diabetic rats via regulation of PI3K/AKT/FoxO1 pathway. Int. J. Immunopathol. Pharmacol. 2022, 36, 3946320221137435.
[60]	Li, H.C.; Liang, J.J.; Han, M.Z.; Gao, Z.P. Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: a review. J. Adv. Res. 2025, 68, 43–62.
[61]	Ren, F.J.; Li, Y.; Luo, H.Y.; Gao, S.; Jiang, S.S.; Yang, J.; Rao, C.L.; Chen, Y.; Peng, C. Extraction, detection, bioactivity, and product development of luteolin: a review. Heliyon. 2024, 10, e41068.
[62]	Li, L.; Jiang, W.F.; Yu, B.J.; Liang, H.Q.; Mao, S.H.; Hu, X.W.; Feng, Y.; Xu, J.D.; Chu, L.S. Quercetin improves cerebral ischemia/reperfusion injury by promoting microglia/macrophages M2 polarization via regulating PI3K/Akt/NF-κB signaling pathway. Biomed. Pharmacother. 2023, 168, 115653.
[63]	Syama, H.P.; Arya, A.D.; Dhanya, R.; Nisha, P.; Sundaresan, A.; Jacob, E.; Jayamurthy, P. Quantification of phenolics in Syzygium cumini seed and their modulatory role on tertiary butyl-hydrogen peroxide-induced oxidative stress in H9c2 cell lines and key enzymes in cardioprotection. J. Food Sci. Technol. 2017, 54, 2115–2125.
[64]	Rajizadeh, M.A.; Bejeshk, M.A.; Doustimotlagh, A.H.; Najafipour, H.; Eftekhari, M.; Mahmoodi, M.; Azizi, M.; Rostamabadi, F.; Pourghadamyari, H. The alleviating impacts of quercetin on inflammation and oxidant-antioxidant imbalance in rats with allergic asthma. Iran. J. Allergy Asthma Immunol. 2023, 22, 138–149.
[65]	Wang, J.C.; Ding, L.L.; Wang, K.; Huang, R.X.; Yu, W.J.; Yan, B.Z.; Wang, H.W.; Zhang, C.; Yang, Z.J.; Liu, Z.P. Role of endoplasmic reticulum stress in cadmium-induced hepatocyte apoptosis and the protective effect of quercetin. Ecotoxicol. Environ. Saf. 2022, 241, 113772.
[66]	Yang, H.; Li, D.D.; Gao, G.L. Kaempferol alleviates hepatic injury in nonalcoholic steatohepatitis (NASH) by suppressing neutrophil-mediated NLRP3-ASC/TMS1-caspase 3 signaling. Molecules. 2024, 29, 2630.
[67]	Huang, L.Y.; Tan, L.P.; Lv, Z.; Chen, W.H.; Wu, J.Z. Pharmacology of bioactive compounds from plant extracts for improving non-alcoholic fatty liver disease through endoplasmic reticulum stress modulation: a comprehensive review. Heliyon. 2024, 10, e25053.
[68]	Tie, F.F.; Ding, J.; Hu, N.; Dong, Q.; Chen, Z.; Wang, H.L. Kaempferol and kaempferide attenuate oleic acid-induced lipid accumulation and oxidative stress in HepG2 cells. Int. J. Mol. Sci. 2021, 22, 8847.
[69]	Termkwancharoen, C.; Malakul, W.; Phetrungnapha, A.; Tunsophon, S. Naringin ameliorates skeletal muscle atrophy and improves insulin resistance in high-fat-diet-induced insulin resistance in obese rats. Nutrients. 2022, 14, 4120.
[70]	Wang, Q.Y.; Ou, Y.J.; Hu, G.M.; Wen, C.; Yue, S.S.; Chen, C.; Xu, L.; Xie, J.W.; Dai, H.; Xiao, H.; Zhang, Y.Y.; Qi, R. Naringenin attenuates non-alcoholic fatty liver disease by down-regulating the NLRP3/NF-κB pathway in mice. Br. J. Pharmacol. 2020, 177, 1806–1821.
[71]	Zhang, B.H.; Wan, S.S.; Liu, H.; Qiu, Q.M.; Chen, H.; Chen, Z.Y.; Wang, L.; Liu, X.H. Naringenin alleviates renal ischemia reperfusion injury by suppressing ER stress-induced pyroptosis and apoptosis through activating Nrf2/HO-1 signaling pathway. Oxid. Med. Cell Longev. 2022, 2022, 5992436.
[72]	Li, J.D.; Wang, T.Q.; Liu, P.P.; Yang, F.Y.; Wang, X.D.; Zheng, W.L.; Sun, W.L. Hesperetin ameliorates hepatic oxidative stress and inflammation via the PI3K/AKT-Nrf2-ARE pathway in oleic acid-induced HepG2 cells and a rat model of high-fat diet-induced NAFLD. Food Funct. 2021, 12, 3898–3918.
[73]	Abdou, H.M.; Hamaad, F.A.; Ali, E.Y.; Ghoneum, M.H. Antidiabetic efficacy of Trifolium alexandrinum extracts hesperetin and quercetin in ameliorating carbohydrate metabolism and activating IR and AMPK signaling in the pancreatic tissues of diabetic rats. Biomed. Pharmacother. 2022, 149, 112838.
[74]	Xie, Q.; Gao, S.Q.; Lei, M.; Li, Z.N. Hesperidin suppresses ERS-induced inflammation in the pathogenesis of non-alcoholic fatty liver disease. Aging. 2022, 14, 1265–1279.
[75]	Garbiec, E.; Cielecka-Piontek, J.; Kowalówka, M.; Hołubiec, M.; Zalewski, P. Genistein-opportunities related to an interesting molecule of natural origin. Molecules. 2022, 27, 815.
[76]	Yin, Y.M.; Liu, H.H.; Zheng, Z.C.; Lu, R.R.; Jiang, Z.Q. Genistein can ameliorate hepatic inflammatory reaction in nonalcoholic steatohepatitis rats. Biomed. Pharmacother. 2019, 111, 1290–1296.
[77]	Seidemann, L.; Krüger, A.; Kegel-Hübner, V.; Seehofer, D.; Damm, G. Influence of genistein on hepatic lipid metabolism in an in vitro model of hepatic steatosis. Molecules. 2021, 26, 1156.
[78]	Pathak, M.P.; Pathak, K.; Saikia, R.; Gogoi, U.; Patowary, P.; Chattopadhyay, P.; Das, A. Therapeutic potential of bioactive phytoconstituents found in fruits in the treatment of non-alcoholic fatty liver disease: a comprehensive review. Heliyon. 2023, 9, e15347.
[79]	Chhimwal, J.; Anand, P.; Mehta, P.; Swarnkar, M.K.; Patial, V.; Pandey, R.; Padwad, Y. Metagenomic signatures reveal the key role of phloretin in amelioration of gut dysbiosis attributed to metabolic dysfunction-associated fatty liver disease by time-dependent modulation of gut microbiome. Front. Microbiol. 2023, 14, 1210517.
[80]	Liou, C.J.; Wu, S.J.; Shen, S.C.; Chen, L.C.; Chen, Y.L.; Huang, W.C. Phloretin ameliorates hepatic steatosis through regulation of lipogenesis and Sirt1/AMPK signaling in obese mice. Cell Biosci. 2020, 10, 114.
[81]	Yan, T.T.; Wang, H.; Cao, L.J.; Wang, Q.; Takahashi, S.; Yagai, T.; Li, G.L.; Krausz, K.W.; Wang, G.J.; Gonzalez, F.J.; Hao, H.P. Glycyrrhizin alleviates nonalcoholic steatohepatitis via modulating bile acids and meta-inflammation. Drug Metab. Dispos. 2018, 46, 1310–1319.
[82]	Liou, C.J.; Lee, Y.K.; Ting, N.C.; Chen, Y.L.; Shen, S.C.; Wu, S.J.; Huang, W.C. Protective effects of licochalcone a ameliorates obesity and non-alcoholic fatty liver disease via promotion of the sirt-1/AMPK pathway in mice fed a high-fat diet. Cells. 2019, 8, 447.
[83]	Li, J.H.; Sapper, T.N.; Mah, E.; Rudraiah, S.; Schill, K.E.; Chitchumroonchokchai, C.; Moller, M.V.; McDonald, J.D.; Rohrer, P.R.; Manautou, J.E.; Bruno, R.S. Green tea extract provides extensive Nrf2-independent protection against lipid accumulation and NFκB pro-inflammatory responses during nonalcoholic steatohepatitis in mice fed a high-fat diet. Mol. Nutr. Food Res. 2016, 60, 858–870.
[84]	Sasaki, G.Y.; Li, J.H.; Cichon, M.J.; Riedl, K.M.; Kopec, R.E.; Bruno, R.S. Green tea extract treatment in obese mice with nonalcoholic steatohepatitis restores the hepatic metabolome in association with limiting endotoxemia-TLR4-NFκB-mediated inflammation. Mol. Nutr. Food Res. 2019, 63, e1900811.
[85]	Hou, H.M.; Yang, W.L.; Bao, S.Q.; Cao, Y.L. Epigallocatechin gallate suppresses inflammatory responses by inhibiting toll-like receptor 4 signaling and alleviates insulin resistance in the livers of high-fat-diet rats. J. Oleo Sci. 2020, 69, 479–486.
[86]	Zhu, L.F.; Cao, F.L.; Hu, Z.M.; Zhou, Y.P.; Guo, T.Y.; Yan, S.S.; Xie, Q.T.; Xia, X.X.; Yuan, H.Y.; Li, G.Y.; Luo, F.J.; Lin, Q.L. Cyanidin-3-O-glucoside alleviates alcoholic liver injury via modulating gut microbiota and metabolites in mice. Nutrients. 2024, 16, 694.
[87]	Xu, J.Q.; Shen, J.Y.; Yuan, R.L.; Jia, B.N.; Zhang, Y.W.; Wang, S.J.; Zhang, Y.; Liu, M.Y.; Wang, T. Mitochondrial targeting therapeutics: promising role of natural products in non-alcoholic fatty liver disease. Front. Pharmacol. 2021, 12, 796207.
[88]	Ye, X.; Chen, W.; Huang, X.F.; Yan, F.J.; Deng, S.G.; Zheng, X.D.; Shan, P.F. Anti-diabetic effect of anthocyanin cyanidin-3-O-glucoside: data from insulin resistant hepatocyte and diabetic mouse. Nutr. Diabetes. 2024, 14, 7.
[89]	Tung, Y.T.; Zeng, J.L.; Ho, S.T.; Xu, J.W.; Li, S.M.; Wu, J.H. Anti-NAFLD effect of djulis hull and its major compound, rutin, in mice with high-fat diet (HFD)-induced obesity. Antioxidants. 2021, 10, 1694.
[90]	Meng, D.C.; Zhang, F.X.; Yu, W.F.; Zhang, X.; Yin, G.L.; Liang, P.P.; Feng, Y.N.; Chen, S.W.; Liu, H.S. Biological role and related natural products of SIRT1 in nonalcoholic fatty liver. Diabetes Metab. Syndr. Obes. 2023, 16, 4043–4064.
[91]	Liang, X.F.; Wang, C.; Sun, Y.; Song, W.; Lin, J.; Li, J.S.; Guan, X.R. p62/mTOR/LXRα pathway inhibits cholesterol efflux mediated by ABCA1 and ABCG1 during autophagy blockage. Biochem. Biophys. Res. Commun. 2019, 514, 1093–1100.
[92]	EL-Shial, E.M.; Kabbash, A.; El-Aasr, M.; El-Feky, O.A.; El-Sherbeni, S.A. Elucidation of natural components of gardenia thunbergia thunb. leaves: effect of methanol extract and rutin on non-alcoholic fatty liver disease. Molecules. 2023, 28, 879.
[93]	Zhao, X.; Wang, H.X.; Yang, Y.; Gou, Y.T.; Wang, Z.Y.; Yang, D.Y.; Li, C. Protective effects of silymarin against D-gal/LPS-induced organ damage and inflammation in mice. Drug Des. Devel. Ther. 2021, 15, 1903–1914.
[94]	Chen, Y.H.; Lin, H.; Wang, Q.; Hou, J.W.; Mao, Z.J.; Li, Y.G. Protective role of silibinin against myocardial ischemia/reperfusion injury-induced cardiac dysfunction. Int. J. Biol. Sci. 2020, 16, 1972–1988.
[95]	Ali, H.; Jahan, A.; Samrana, S.; Ali, A.; Ali, S.; Kabir, N.; Ali, A.; Ullah, R.; Mothana, R.A.; Murtaza, B.N.; Kalim, M. Hepatoprotective potential of pomegranate in curbing the incidence of acute liver injury by alleviating oxidative stress and inflammatory response. Front. Pharmacol. 2021, 12, 694607.
[96]	Rani, R.; Sharma, A.; Wang, J.; Kumar, S.; Polaki, U.S.; Gandhi, C.R. Endotoxin-stimulated hepatic stellate cells augment acetaminophen-induced hepatocyte injury. Am. J. Pathol. 2022, 192, 518–535.
[97]	Pferschy-Wenzig, E.M.; Atanasov, A.G.; Malainer, C.; Noha, S.M.; Kunert, O.; Schuster, D.; Heiss, E.H.; Oberlies, N.H.; Wagner, H.; Bauer, R.; Dirsch, V.M. Identification of isosilybin a from milk thistle seeds as an agonist of peroxisome proliferator-activated receptor gamma. J. Nat. Prod. 2014, 77, 842–847.